# Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial

> **NCT03578822** · PHASE3 · COMPLETED · sponsor: **Tasly Biopharmaceuticals Co., Ltd.** · enrollment: 149 (actual)

## Conditions studied

- Acute Ischaemic Stroke

## Interventions

- **DRUG:** Recombinant human urokinase
- **DRUG:** Aspirin
- **DRUG:** rhPro-UK simulation agent
- **DRUG:** Aspirin simulation agent

## Key facts

- **NCT ID:** NCT03578822
- **Lead sponsor:** Tasly Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-10
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-03-01
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03578822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03578822, "Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03578822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*